#letermovir

[impomed]

Anagrelide 0.5 mg is an effective medication for managing high platelet counts, especially in conditions like essential thrombocythemia (ET). By reducing platelet production in the bone marrow, Anagrelide helps lower the risk of serious complications such as strokes and heart attacks.In Impomed Healthcare plays a crucial role in providing access to Anagrelide 0.5 mg in India, ensuring patients receive this important treatment. With a focus on quality and patient care, Impomed collaborates with healthcare providers to make this medication widely available. If you or someone you know is facing high platelet levels, consulting with a healthcare provider about Anagrelide 0.5 mg can be a vital step toward better health.

For more information click on this link-:https://www.impomedhealthcare.com

[organicmarketresearch]

Global Letermovir Injection Market.

Global Letermovir Injection industry vary by region and are important and expanding. Below is a quick summary of the industry's regional analysis.

[biotech-news-feed]

Opinion/decision on a Paediatric investigation plan (PIP): Prevymis, Letermovir, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0455/2023 #BioTech #science

[antiherpetic2cmt-blog]

LETERMOVIR

by Greziel Guanzon

Trade Name: Prevymis

Routes of Administration: Oral

Tablet: 240 mg, 480mg

Solution for injection: 20mg/mL  (vials contain 240mg/12mL or 480mg/24ml)

1. What is Letermovir?

An antiviral drug for the treatment of cytomegalovirus (CMV) infections. This drug is orally bioavailable and an inhibitor of the subunit of the viral terminase complex of cytomegalovirus (CMV).

Upon oral administration, the drug binds to the viral terminase complex of CMV and prevents the cleavage of concemeric DNA into monomeric length DNA. Letermovir interfere with viral DNA processing and subsequent viral DNA packaging into procapsids that results to CMV replication being blocked and its infection prevented.  

    Letermovir is used in the prophylaxis of cytomegalovirus (CMV) infection in allogenic hematopoietic stem cell transplant patients.  

      Letermovir has a priority and orphan drug status from FDA and is marketed as Prevymis.

Sources:

National Center for Biotechnology Information. PubChem Database. Letermovir, CID=45138674, https://pubchem.ncbi.nlm.nih.gov/compound/45138674 (accessed on May 15, 2019)

[bidhuan]

Letermovir Sebagai Obat Baru Antiviral pada Cytomegalovirus

Letermovir Sebagai Obat Baru Antiviral pada Cytomegalovirus

Farmasetika.com – Letermovir (sebelumnya dikenal sebagai AIC246) adalah agen anti-CMÞ1V baru yang sangat potensial dengan mekanisme tindakan baru yang menargetkan subunit terminologi virus pUL56, (Lishka et al., 2010; Goldner et al., 2011) komponen dari terminase Kompleks yang terlibat dalam pembelahan DNA virus yang tidak memiliki target enzim setara dalam tubuh manusia.

Dengan demikian,…

[tilliwriteapine]

The saga continues of drugs I cannot fucking pronounce. Chemotherapy? I can do that. ANTIVIRALS? NOPE. Gah. Who knew letermovir would be so difficult.

[shruticmi-universe]

HPV & CMV THERAPEUTICS MARKET ANALYSIS

Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market, by Drug Type (HPV Therapeutics (Immunomodulatory Agents, Keratolytic Agents, Anti-Neoplastic Agents, and Sinecatechins) and CMV Therapeutics (Ganciclovir/Valaganciclovir, Foscarnet, and  Cidifovir), by Application (HPV Therapeutics- Genital warts, Cervical cancer, Epidermodysplasia Verrucifdormis, and Others) and (CMV Therapeutics-CMV Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Cytomegalovirus (CMV) infections spread through body fluids such as saliva, semen, breast milk, and urine. Signs and symptoms of the infections include, fatigue, fever, diarrhea, pneumonia, and hepatitis, shortness of breath, gastrointestinal ulceration, and bleeding.

Although no treatment for the infection caused by human papillomavirus (HPV) is available, symptoms can be treated. Most sexually active men and women suffer from HPV infections. The infections spread through oral, vaginal or anal sex. HPV can also be transmitted during birth to infant and can lead to genital or respiratory infections.

Market Dynamics

Increasing collaboration activities of major players is expected to propel growth of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market. For instance, in November 2018, GeoVax Labs Inc. announced collaboration with Virometix. The collaboration focuses on development of therapeutic vaccines for HPV infections. This collaboration will include preclinical animal testing of GeoVax’s MVA-Vectored HPV vaccines candidates in combination with Virometix synthetic HPV vaccines candidates.

Moreover, increasing regulatory approvals for novel therapies is expected to boost the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market growth. For instance, in November 2017, Merck received the U.S. Food and Drug Administration approval for its Prevymis (letermovir) tablets and intravenous (IV) injection for prophylaxis of CMV infections and CMV seropositive recipients.

Key features of the study:

This report provides     in-depth analysis of the human papillomavirus (HPV)     and cytomegalovirus (CMV) therapeutics market size (US$ Mn), and     cumulative annual growth rate (CAGR (%)) for the forecast period: 2018 –     2026, considering 2017, as the base year

It elucidates potential     revenue opportunity across different segments and explains attractive     investment proposition matrix for this market

This study also provides key     insights about market drivers, restraints, opportunities, new product     launches or approval, market trends, regional outlook, and competitive     strategies adopted by key players

It profiles key players in     the global human papillomavirus (HPV) and cytomegalovirus (CMV)     therapeutics market based on the following parameters – company overview,     financial performance, product portfolio, geographical presence,     distribution strategies, key developments, and strategies

Key players covered as a     part of this study include, , Allergan, Bausch Health, GlaxoSmithKline,     Lee’s Pharmaceutical Holdings, Merck Sharp & Dohme, Fougera     Pharmaceuticals, Clinigen Group plc., Perrigo Company plc., Roche Holding     AG, Biotest AG, and Fresenius Kabi

Insights from this report     would allow marketers and management authorities of companies to make     informed decision with respect to their future product launch,     governmental initiatives, technological up-gradation, market expansion,     and marketing tactics

The global human papillomavirus (HPV)     and cytomegalovirus (CMV) therapeutics market report caters to various     stakeholders in this industry, including investors, product manufacturers,     distributors and suppliers for anesthesia device market, research and     consulting firms, new entrants, and financial analysts

 Request the sample copy here:

https://www.coherentmarketinsights.com/insight/request-sample/2707

Request the pdf brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2707

Detailed Segmentation:

   Interleukins

   Cytokines

   Chemokine

   Others

     TCA (Trichloroacetic        Acid)

   Bichloracetic Acid

    Ganciclovir/Valganciclovir

  Foscarnet

  Cidifovir

     Genital warts

   Cervical cancer

   Epidermodysplasia        Verrucifdormis

   Others

     CMV Retinitis

   Pneumonia

   Gastrointestinal ulcers

   Encephalitis

   Others

     Hospitals Pharmacies

   Retail Pharmacies

   Online Pharmacies

    U.S.

  Canada

      Interleukins

    Cytokines

    Chemokine

    Others

        TCA (Trichloroacetic         Acid)

    Bichloracetic Acid

       Ganciclovir/Valganciclovir

   Foscarnet

   Cidifovir

     Genital warts

   Cervical cancer

   Epidermodysplasia        Verrucifdormis

   Others

     CMV Retinitis

   Pneumonia

   Gastrointestinal ulcers

   Encephalitis

   Others

    Hospitals Pharmacies

  Retail Pharmacies

  Online Pharmacies

    U.K.

  Germany

  Italy

  Spain

  France

  Russia

  Rest of Europe

      Interleukins

    Cytokines

    Chemokine

    Others

        TCA (Trichloroacetic         Acid)

    Bichloracetic Acid

       Ganciclovir/Valganciclovir

   Foscarnet

   Cidifovir

     Genital warts

   Cervical cancer

   Epidermodysplasia        Verrucifdormis

   Others

     CMV Retinitis

   Pneumonia

   Gastrointestinal ulcers

   Encephalitis

   Others

    Hospitals Pharmacies

  Retail Pharmacies

  Online Pharmacies

    Australia

  India

  China

  Japan

  ASEAN

  South Korea

  Rest of Asia Pacific

      Interleukins

    Cytokines

    Chemokine

    Others

        TCA (Trichloroacetic         Acid)

    Bichloracetic Acid

       Ganciclovir/Valganciclovir

   Foscarnet

   Cidifovir

     Genital warts

   Cervical cancer

   Epidermodysplasia Verrucifdormis

   Others

     CMV Retinitis

   Pneumonia

   Gastrointestinal ulcers

   Encephalitis

   Others

    Hospitals Pharmacies

  Retail Pharmacies

  Online Pharmacies

    Brazil

  Mexico

  Argentina

  Rest of Latin America

      Interleukins

    Cytokines

    Chemokine

    Others

        TCA (Trichloroacetic         Acid)

    Bichloracetic Acid

       Ganciclovir/Valganciclovir

   Foscarnet

   Cidifovir

     Genital warts

   Cervical cancer

   Epidermodysplasia        Verrucifdormis

   Others

     CMV Retinitis

   Pneumonia

   Gastrointestinal ulcers

   Encephalitis

   Others

    Hospitals Pharmacies

  Retail Pharmacies

  Online Pharmacies

    GCC

  Israel

  Rest of Middle East

      Interleukins

    Cytokines

    Chemokine

    Others

        TCA (Trichloroacetic         Acid)

    Bichloracetic Acid

       Ganciclovir/Valganciclovir

   Foscarnet

   Cidifovir

     Genital warts

   Cervical cancer

   Epidermodysplasia Verrucifdormis

   Others

     CMV Retinitis

   Pneumonia

   Gastrointestinal ulcers

   Encephalitis

   Others

    Hospitals Pharmacies

  Retail Pharmacies

  Online Pharmacies

    South Africa

  Central Africa

  North Africa

      Interleukins

    Cytokines

    Chemokine

    Others

        TCA (Trichloroacetic         Acid)

    Bichloracetic Acid

       Ganciclovir/Valganciclovir

   Foscarnet

   Cidifovir

     Genital warts

   Cervical cancer

   Epidermodysplasia        Verrucifdormis

   Others

     CMV Retinitis

   Pneumonia

   Gastrointestinal ulcers

   Encephalitis

   Others

    Hospitals Pharmacies

  Retail Pharmacies

  Online Pharmacies

   GlaxoSmithKline*

  Company Overview

  Product Portfolio

  Financial Performance

  Recent Highlights

  Strategies

   Allergan

 Bausch Health

 Lee’s Pharmaceutical Holdings

 Merck Sharp & Dohme

 Fougera Pharmaceuticals

 Clinigen Group plc.

 Perrigo Company plc.

 Roche Holding AG

 Biotest AG

 Fresenius Kabi

  Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2707

 About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized market research     service

Industry analysis services

Business consulting services

Market intelligence services

Long term engagement model

Country specific analysis

 Explore cmi services here

Contact Us:

Mr. shah

Coherent Market Insights Pvt. Ltd.

Address:  Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email:  sales@coherentmarketinsights.com

 Source: https://www.coherentmarketinsights.com/market-insight/human-papillomavirus-hpv-and-cytomegalovirus-cmv-therapeutics-market-2707

[healthcare00897]

Cytomegalovirus  Infection Treatment and Diagnosis Market show significant growth To 2026

Cytomegalovirus (CMV) is a virus that belongs to herpes virus family that remain dormant in the human body. CMV infection can occur in people of all ages worldwide. CMV is a communicable disease that spreads through body fluids such as saliva, blood, urine, semen, and breast milk. Presence of CMV infection can be detected by various testing methods based on which the global cytomegalovirus infection treatment and diagnosis market can be analyzed:

   Serologic test

   Polymerase chain reaction (PCR) test

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/167

CMV diagnosis is very critical in pregnant women and immunocompromised individuals. Enzyme-linked immunoassay test is the most widely used serologic testing for CMV infection in laboratories. Besides, PCR technique is also widely implemented for samples of saliva, and urine. Awareness about the infection is essential as most of the cases go undiagnosed at early stages as the disease is asymptomatic.

Cytomegalovirus Infection Market: Treatment Approach

People diagnosed with high risk of CMV infection may be given anti-viral medications to prevent the disease to get in to active stage. There is no cure available for treating the CMV infection. Ganciclovir, Val ganciclovir, Cidofovir, Valacyclovir and Foscarnet are few major anti-viral medications prescribed. In some cases, CMV immune globulin contains antibodies (proteins) may be prescribed to prevent CMV infection. There are certain products in pipeline which includes Cytovir CMV, Letermovir, CytoTect CP 70, Brincidofovir and ASP0113, commercialization of which is expected to fuel the global CMV infection treatment and diagnosis market growth in the near future.

Vital Statistics For The Global Cytomegalovirus Infection Treatment And Diagnosis Market

Besides, diagnosis of new CMV cases would be a propelling factor for global cytomegalovirus infection treatment and diagnosis market. The Public Health Agency of Canada estimates that 40%-100% of the global population have CMV antibody present in their body. Immunocompromised patients (HIV, organ transplant), premature infants, newborns and with congenital CMV are at high risk of developing serious illness with CMV infection.

According to the Centers for Disease Control and Prevention (CDC), one in every 150 infants are born with congenital cytomegalovirus (CMV) infection in the U.S. However, only one in five infants infected with CMV have long term health problems. Prevailing infection rates and demand for effective treatment therapies would be thrusting the cytomegalovirus infection treatment and diagnosis market growth.

Cmv Infection Treatment And Diagnosis Market: Regional Overview

Early diagnosis practices would drive the global cytomegalovirus infection treatment and diagnosis market in developed regions such as North America and Europe, where accessibility to advanced diagnostic and treatment facilities is high compared to the emerging economies. For market players in the diagnosis and treatment of CMV infection, ensuring accessibility and healthcare investment in emerging nations would be critical to generate better return on investments.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/167

Some of the major players in the global cytomegalovirus infection treatment and diagnosis market are Merck & Co. Inc., Cell Medical Ltd., Chimerix, Inc., Affymetrix, Inc., Abbott Laboratories, Inc., Becton, Dickinson and Company, Johnson & Johnson, Bio-Rad Laboratories, Inc., and F. Hoffmann-La Roche Ltd.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

[padansk]

In the space of a month or two

I worte this in July 2018 but just didnt publish it as I always intended to finish it off, I never did and so many things have happened since this.

We went on holiday for the first time in just over three years in April. Majorca was our destinaion of choice. The first trip was a sighter, to see if we could do it. Nicola was super apprenhensive, undestanable eh? In hindsight choosing Easyjet as our airflight operator of choice was a bad idea. It was just too busy and once we had boarded the aircraft with Nicola wearing her industrial level face mask to keep other peoples bugs at bay, it came close to being overwhelming. The small child who sat in front of us popped her head over her parents shoulders to say hello was combined with the coughs and sneezing of passengers that seemed to echo and have an increased decibel level way over what seemed natural. At this moment I felt sure was going make Nicola bolt from her seat and ask the attendants to let us off the flight. Her willpower as always perserveered and we made it across to the Balearic isle.

The trip was for a long weekend, five days but we knew straight away that we would want to come back to Majorca. Did I mention the cycling was amazing aswell? On returning to England we immediately booked to go back and this time we would stay in villa in the north of the island. We travelled on a better airline and they looked after Nicola in a really lovely way, I cant praise them enough. We stayed for two weeks in Majorca and it was the best holiday I have ever had. We drove around the spectacular mountains in the north of the island, we walked on beaches, ambled around Palma, and got lost in little villages. It was perfect.

We came home in early May and we could tell that Nicola's skin GVHD was flaring up. As usual we went to the clinic and they gave things the all clear whilst recognising that Nicola now had chronic GVHD on her skin. Whilst all of this was ongoing Nicola continued to take Valganciclovir to keep the constantly reactivating CMV at bay. This was taking a toll on her kidney function which was now at a constant reduced function position. We had been trying to get hold of a new CMV anti viral drug called Letermovir, but had been knocked back on every occasion by the NHS and the Cancer drug funding request team. We spoke to our private medical insurers, and unbelievably they gave it the OK within 24 hours. I have to admit it was an emotional moment when they said yes to it. For a change it felt like someone was on our side and giving us real help. It would take a bit longer to actually get the drug in our hands.

At the same time as all this is going on Nicola also had some skin lesions that had started to become apparent. The specialist nurse referred her to see a consultant. The consultant advised that a biopsy would be needed. That didnt fill us with confidence but we have learned over time not to jump to the worst conclusions on the smallest amount of assessment. The biopsies were done, 8 in total. Nicola whilst in some discomfort, recovered and we went and saw our consultant for the results. He diagnosed HPV and high grade VIN2 in some of the biopsies. What does that mean? Well in short its a pre-cancerous diagnosis. It doesnt mean it will become cancer either today or tomorrow, but its something that needs attention. Nicola having had blood cancer and undergoing one of the highest intensity chemotherapy regimes as well as a stem cell transplant is already pre-disposed to secondary cancers. In short they want to deal with it before it becomes more of an issue than it is. But its not straight forward.

[impomed]

 Liposomal Daunorubicin & Cytarabine (Vyxeos) represents a major breakthrough in treating high-risk acute myeloid leukemia (AML) in India. This innovative therapy combines daunorubicin and cytarabine in a liposomal formulation, enhancing their effectiveness and improving patient outcomes. Particularly beneficial for patients with therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC), Vyxeos provides targeted delivery of chemotherapy with fewer side effects. In India, Impomed Healthcare plays a critical role in making Liposomal Daunorubicin & Cytarabine (Vyxeos) in India accessible to those in need, Impomed ensures that advanced cancer care reaches more patients, offering new hope for those battling aggressive forms of leukemia. Discover how Vyxeos is transforming AML treatment in India.

For more information click on this link-:https://www.impomedhealthcare.com/

[affiliatetejas]

Cytomegalovirus (CMV) Infection Treatment & Diagnosis Market 2026

To Gain More Insights into the Cytomegalovirus (CMV) Infection Treatment and Diagnosis Market, Browse Summary of the Research Report –

Cytomegalovirus (CMV) is a virus that belongs to herpes virus family that remain dormant in the human body. CMV infection can occur in people of all ages worldwide. CMV is a communicable disease that spreads through body fluids such as saliva, blood, urine, semen, and breast milk. Presence of CMV infection can be detected by various testing methods based on which the global cytomegalovirus infection treatment and diagnosis market can be analyzed:

Serologic test

Polymerase chain reaction (PCR) test

https://www.coherentmarketinsights.com/ongoing-insight/cytomegalovirus-infection-treatment-and-diagnosis-market-167

CMV diagnosis is very critical in pregnant women and immunocompromised individuals. Enzyme-linked immunoassay test is the most widely used serologic testing for CMV infection in laboratories. Besides, PCR technique is also widely implemented for samples of saliva, and urine. Awareness about the infection is essential as most of the cases go undiagnosed at early stages as the disease is asymptomatic.

People diagnosed with high risk of CMV infection may be given anti-viral medications to prevent the disease to get in to active stage. There is no cure available for treating the CMV infection. Ganciclovir, Val ganciclovir, Cidofovir, Valacyclovir and Foscarnet are few major anti-viral medications prescribed. In some cases, CMV immune globulin contains antibodies (proteins) may be prescribed to prevent CMV infection. There are certain products in pipeline which includes Cytovir CMV, Letermovir, CytoTect CP 70, Brincidofovir and ASP0113, commercialization of which is expected to fuel the global CMV infection treatment and diagnosis market growth in the near future.

“We Do Offer Sample of Cytomegalovirus (CMV) Infection Treatment and Diagnosis Market Report. Kindly go through the follow information in order to access sample copy.”

https://www.coherentmarketinsights.com/insight/request-sample/167

Table of Contents

https://www.coherentmarketinsights.com/ongoing-insight/toc/167

Top players in the market

Major institutes are focused on launching various programs focused on R&D activities related to cytomegalovirus (CMV) infection. For instance, in August 2019, The UW Program for Advanced Cell Therapy (PACT) launched first-in-US cell-therapy trial for kidney transplant patients that will deploy virus-specific white blood cells for the treatment of severe cytomegalovirus (CMV) infection after kidney transplantation.

Moreover, in January 2019, a team of researchers from Lions Eye Institute (LEI), a medical research institute affiliated with the University of Western Australia, discovered a new method to prevent reactivation of CMV in mouse models by injecting them with their own antibodies. The research is expected to offer a new strategy to control CMV reactivation in humans.

Research methodology adopted by Coherent Market Insights

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

Primary Research (Trade Surveys and Experts Interviews)

Desk Research

Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Request A Sample Copy Cytomegalovirus (CMV) Infection Treatment and Diagnosis Market Report Click here:

https://www.coherentmarketinsights.com/insight/request-sample/167

Get PDF Research Report Brochure @

https://www.coherentmarketinsights.com/insight/request-pdf/167

Buy Now this Premium Report to Grow your Business @

https://www.coherentmarketinsights.com/insight/buy-now/167

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

Contact Us:

Name: Mr. Raj Shah

Email: sales@coherentmarketinsights.com

Phone: US +12067016702

Country: United States

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

[rohinic123-blog]

Human Papillomavirus and Cytomegalovirus Therapeutics Market Shares, Strategies and Opportunities 2027

Human Papillomavirus and Cytomegalovirus Therapeutics Market: Introduction

According to the report, the global human papillomavirus therapeutics market was valued at ~US$ 3 Bn and the global cytomegalovirus therapeutics market was valued at ~US$ 575 Mn in 2018. The two markets are projected to expand at CAGRs of ~4% and ~6%, respectively, from 2019 to 2027. Human papillomavirus (HPV) and cytomegalovirus (CMV) are DNA viruses that cause serious health conditions in patients of all ages. HPV is one of the most common sexually transmitted viruses causing genital infections and cancers. CMV is an opportunistic pathogen affecting immunocompromised patients.

Hence, transplant and HIV patients are at high risk of acquiring CMV infections. Therapeutic options for HPV and CMV infections included in this report are various drug classes such as antivirals, immunomodulators, and keratolytics. North America dominated the global human papillomavirus and cytomegalovirus therapeutics market in 2018 and the trend is expected to continue during the forecast period.

Request For Covid19 Impact Analysis –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=77194

Rise in Prevalence of HPV Infection and Recurring Nature of CMV Diseases Drive Global Market

Rise in prevalence of HPV infections in developing and underdeveloped countries is a major driver of the human papillomavirus therapeutics market. Grants from governments and international organizations for cancer treatment and proactive initiatives by governments also boost the growth of the human papillomavirus therapeutics market. For instance, the National Institute of Dental and Craniofacial Research (NIDCR) supports a range of basic, translational, and clinical HPV-related cancer research to address this emerging public health concern and invested US$ 8 Mn in the research on HPV-positive cancer in 2017.

Recurring nature of cytomegalovirus infections and diseases indicated by CMV is the major factor fueling the growth of the cytomegalovirus therapeutics market. Moreover, the development of novel molecules for CMV infection treatment and product approval by regulatory bodies accelerates the growth of the global cytomegalovirus therapeutics market.

Planning To Lay Down Future Strategy? Request Brochure Of Human Papillomavirus and Cytomegalovirus Therapeutics Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=77194

Immunomodulators and Ganciclovir/Valganciclovir Held Major Shares of Human Papillomavirus and Cytromegalovirus Therapeutics Market

In terms of drug class, the global human papillomavirus and cytromegalovirus therapeutics market has been classified into human papillomavirus therapeutics (immunomodulators, keratolytics, antineoplastics, and sinecatechins) and cytromegalovirus therapeutics (Ganciclovir/Valganciclovir, Foscavir [Foscarnet], Cidofovir [Vistide], Letermovir [Prevymis], and others. The immunomodulators sub-segment dominated the human papillomavirus therapeutics segment in 2018 due to first-line treatment in HPV infection. The ganciclovir/valganciclovir segment accounted for major market share in 2018, owing to better antiviral activity and lesser side effects.

Genital Cancer and Retinitis to be Promising Applications

Based on application, the global human papillomavirus and cytromegalovirus therapeutics market has been categorized into human papillomavirus therapeutics (genital warts, genital cancer, oral papillomas, and others) and cytromegalovirus therapeutics (retinitis, gastrointestinal ulcer, pneumonia, encephalitis, and others). Genital cancer is anticipated to be a highly lucrative sub-segment during the forecast period due to rise in prevalence and better therapeutic options for genital cancer treatment. Retinitis is expected to be a highly attractive sub-segment from 2019 to 2027, owing to higher incidence rate and rise in awareness about therapeutic products.

To Obtain All-Inclusive Information On Forecast Analysis Of Human Papillomavirus and Cytomegalovirus Therapeutics Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=77194

Retail Pharmacies to be Dominant Segment

In terms of distribution channel, the global human papillomavirus and cytomegalovirus therapeutics market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment dominated the global human papillomavirus and cytromegalovirus therapeutics in 2018. Rise in number of retail pharmacies and availability of generic drugs are the major factors attributed to the segment’s market dominance.

North America to Dominate Global Market

In terms of region, the global human papillomavirus and cytomegalovirus therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for major share of the global human papillomavirus and cytomegalovirus therapeutics market in 2018 due to higher number of cases of HPV & CMV infections, increase in number of approved products, and government funding for research. An article published by NCBI stated that CMV seroprevalence ranges from about 40% to 50% in highly developed countries to nearly 95% in developing countries, and from about 30% in childhood to 50% in women of childbearing age and up to 60% to 70% in adults. Asia Pacific is likely to be a highly lucrative market for HPV and CMV therapeutics, owing to large patient population affected by CMV, rise in awareness about the disease, and increase in demand for generics.

Competition Landscape

Merck & Co., Inc., Bausch & Lomb Incorporated (Bausch Health Companies, Inc.), and F. Hoffmann-La Roche Ltd. are the leading players in the global human papillomavirus and cytomegalovirus therapeutics market. The global human papillomavirus and cytomegalovirus therapeutics market is fragmented in terms of number of players with entry of several players particularly in generics. Key players in the global market include Merck & Co., Inc., Bausch & Lomb Incorporated (Bausch Health Companies, Inc.), AbbVie, Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Clinigen Group plc., Pfizer, Inc., and Cipla, Inc. New product launches, mergers & acquisitions, and patient assistance or awareness programs are the major strategies adopted by companies in the global human papillomavirus and cytomegalovirus therapeutics market.

More Trending Reports by Transparency Market Research –

Endocrine Testing Market -

https://www.prnewswire.com/news-releases/endocrine-testing-market-to-hit-us12-8-billion-by-2023--says-tmr-300817560.html

Multi-parameter Patient Monitoring Equipment Market -

https://www.biospace.com/article/multi-parameter-patient-monitoring-equipment-market-constant-rise-in-incidence-of-chronic-diseases-is-one-of-the-key-driver/

[otcfdaregtration]

PREVYMIS (letermovir) tablet, film coated PREVYMIS (letermovir) injection, solution [Merck Sharp & Dohme Corp.]

Updated Date: Tue, 18 Feb 2020 00:00:00 EST from https://fda.report/DailyMed/1b49df80-be4f-47e0-a0b7-123f3e69395b4

[shristipbi]

Cytomegalovirus Infection Treatment Market   Growth, Analysis, Key Players, and Forecast to 2025

Precision Business Insights (PBI) in its report titled “Global Cytomegalovirus Infection Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

 The global cytomegalovirus infection treatment market was valued at US$ 1,327.3 Mn in 2018 and growing at a CAGR of XX% over the forecast period owing to increasing prevalence of CMV infections and increasing awareness among the patients regarding the herpes diseases. For instance, mainly CMV effects young children but in United States, half of the adults under age 30 are infected by CMV. The support from the government and development of healthcare infrastructure are expected to support the growth of the market. Moreover, good number of pipeline therapies for that are under the development for the treatment of CMV such as ATA230 (Atara Biotherapeutics), Maribavir (Shire) fuels the growth of the market. However, expiry of patented drugs are expected to restrain the growth of the market.

Global cytomegalovirus infection treatment market segmented on the basis of drug class, infection, distribution channel, and region.

  For more sample: https://www.precisionbusinessinsights.com/request-sample?product_id=15678

 Antiviral Drugs segment accounted for higher revenue share

Based on drug class, global cytomegalovirus infection treatment market segmented into Antiviral Drugs, Foscarnet, Cytovene, Vistide, and others. Antiviral drugs segment market accounted US$ XX Mn in 2018 and projected to dominate over the forecast period due to increasing prevalence of the CMV infections and launch of new products in the market. There are number of products under development for the treatment of CMV infections which is expected to enhance the growth of the market in the future years. However, entry of generic drugs are expected to hamper the growth of the market.

North America is expected to dominate Global Cytomegalovirus Infection Treatment Market

 PBI’s global cytomegalovirus infection treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to regional analysis, North America is expected to account for larger revenue share in 2018 and the same trend is projected to follow over 2019-2025 owing to rapid prevalence of CMV infection. As per Centre for Disease Control and Prevention (CDC), approximately, 80,000 cases of CMV infections were diagnosed in U.S. and Europe. Rising prevalence of cytomegalovirus (CMV) infection in the developing economies and in the areas of lower economic status. Asia-Pacific is anticipated to grow rapidly owing to the large patient pool, and rise in prevalence of many infectious diseases as well as rise in the awareness on cytomegalovirus infections.

Key Developments  

 In Feb 2017, Merck & Co., Inc. started pivotal Phase 3 clinical study of letermovir, an antiviral investigational drug for treating clinically significant cytomegalovirus Infection.

 Key player’s profiles in the report are F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.), AiCuris Anti-infective Cures GmbH (Germany), Vical, Inc. (U.S.), Chimerix, Inc. (U.S.) and ViroPharma (U.S.)

 Detailed Segmentation

 By Drug Class  

o   Antiviral Drugs

o   Foscarnet

o   Cytovene

o   Vistide

o   Others

By Infection  

o   Retinitis

o   Pneumonia

o   Gastroenteritis

o   Others (Mouth Ulcers, Pharyngitis, etc.)

By Distribution Channel

o   Hospital Pharmacies

o   Retail Pharmacies

o   Others

Geography

 o     North America

·         U.S

·         Canada

o     Europe

·         Germany

·         France

·         U.K

·         Italy

·         Spain

·         Russia

·         Poland

·         Rest of Europe

o     Asia-Pacific

·         Japan

·         China

·         India

·         Australia & New Zealand

·         ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)

·         South Korea

·         Rest of Asia-Pacific

o     Latin America

·         Brazil

·         Mexico

·         Argentina

·         Rest of Latin America

o     Middle East and Africa (MEA)

·         Gulf Cooperation Council (GCC) Countries

·         Israel

·         South Africa

·         Rest of MEA

 For more information: https://www.precisionbusinessinsights.com/market-reports/global-cytomegalovirus-infection-treatment-market/

 Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customized market research services based on our client needs.

 Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

[azveille]

Le prix d'ATU de Zolgensma* fixé à 1,945 million d'euros

Avexis (groupe Novartis) a fixé l'indemnité d'autorisation temporaire d'utilisation (ATU) de sa thérapie génique de l'amyotrophie spinale Zolgensma* (onasemnogène abéparvovec) à 1,945 million d'euros pour un traitement, apprend-on à la lecture du tableau sur les médicaments en ATU et post-ATU mis à jour mercredi par le Comité économique des produits de santé (CEPS).

Zolgensma* a obtenu une autorisation de mise sur le marché (AMM) aux Etats-Unis fin mai. Son prix catalogue a été fixé à 2,125 millions de dollars, ce qui en fait le médicament au prix unitaire le plus élevé dans le monde, rappelle-t-on (cf dépêche du 27/05/2019 à 11:25).

A la parité actuelle de 1 euro pour 1,12 dollar, l'indemnité d'ATU de Zolgensma* ressort à 2,178 millions de dollars, c'est-à-dire un niveau supérieur à celui affiché aux Etats-Unis, note-t-on.

En Europe, une demande d'homologation est en cours d'évaluation à l'Agence européenne du médicament (EMA). Novartis espère obtenir une AMM au dernier trimestre.

Il est à noter que le prix d'ATU de Zolgensma* est publié par le CEPS alors que l'Agence nationale de sécurité du médicament et des produits de santé (ANSM) n'a pas encore indiqué sur son site que cette autorisation avait été octroyée.

La même situation est constatée pour la thérapie cellulaire utilisée dans la greffe de cellules souches hématopoïétiques Rivo-cell* (rivogenlecleucel, Bellicum), dont le prix d'ATU est fixé à 348.000 euros pour une injection, et pour le rimiducid (Bellicum), utilisé en cas de rejet du greffon contre l'hôte lors de la même procédure, pour lequel aucun prix n'est mentionné.

Parmi les autres médicaments figurant nouvellement sur la liste publiée mercredi (mise à jour de la précédente datée du 30 décembre 2018), Waylivra* (volanesorsen, Akcea, groupe Ionis), dont l'ATU de cohorte dans le syndrome d’hyperchylomicronémie familial (SHCF) a débuté fin juin, coûte 16.500 euros pour une seringue dosée à 285 mg.

Pour le traitement de la mucopolysaccharidose de type VII Mepsevii* (vestronidase alfa, Ultragenyx), désormais en post-ATU, l'indemnité est à 1.581 euros pour un flacon.

Aucun prix n'est mentionné pour les anticancéreux larotrectinib (Bayer), Libtayo* (cémiplimab, Sanofi), Lorviqua* (lorlatinib, Pfizer) et Vanflyta* (quizartinib, Daiichi Sankyo).

Pour l'antiviral Premvymis* (letermovir), MSD a fixé, pour un comprimé, des prix d'ATU de 166,08 euros pour le 240 mg et de 332,16 euros pour le 480 mg.

Le traitement de l’acidose tabulaire rénale distale ADV7103 (citrate de potassium anhydre + bicarbonate de potassium, Advicenne) coûte 260 euros pour un sachet de granules à 8 mEq et 700 euros pour celui à 24 mEq.

Le stimulant Attentin* (dexamphétamine, HAC Pharma) est à 2.950 euros pour un comprimé.

Trois médicaments de Mylan figurent dans la liste:

Legalon-Sil* (silibiline), indiqué dans l'intoxication avérée ou suspectée à l’amanite phalloïde ou à la lépiote brune, au prix de 600 euros pour un flacon de 350 mg poudre pour solution pour perfusion

l'AVK Marcoumar* (phenprocoumone), à 698 euros pour un comprimé à 3 mg

la ribavirine en solution à diluer pour perfusion Virazole*, à 4.909,72 euros pour un flacon.

L'indemnité de post-ATU du traitement du lymphome cutané Ledaga* (chlorméthine), passé d'Actelion (groupe Johnson & Johnson) à Recordati, a par ailleurs augmenté de près de 40% à 1.800 euros pour un tube de gel.

Enfin, des indemnités ont été fixées pour des médicaments qui apparaissaient sans prix dans la précédente liste.

Pour le traitement du cancer du poumon ALK+ Alunbrig* (brigatinib, Takeda), un comprimé coûte 54,67 euros (dosage à 30 mg) ou 164 euros (dosages à 90 mg et 180 mg).

Pour le traitement du cancer de la prostate Erleada* (apalutamide, Janssen), un comprimé est à 25,839 euros.

Enfin, une seringue du traitement de la polyneuropathie chez les patients atteints d'amylose héréditaire à transthyrétine Tegsedi* (inotersen, Akcea) coûte 8.091,35 euros.

[healthtimetaylor]

Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus.

PMID:  Antivir Ther. 2016 ;21(6):535-539. Epub 2016 Feb 4. PMID: 26844400 Abstract Title:  Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus. Abstract:  BACKGROUND: Human cytomegalovirus (HCMV) infections remain a major problem in immunocompromised patients. Three antiviral agents, ganciclovir (GCV), foscarnet (FOS) and cidofovir (CDV), are currently approved for the treatment of HCMV infections. They all target the viral DNA polymerase and are associated with significant side effects. Combinations of novel antiviral compounds acting on different targets such as artesunate (ART) with currently approved drugs or eventually letermovir or maribavir (MBV) may result in synergistic effects. Here, we evaluated the in vitro activity of a series of two-drug combinations against a wild-type recombinant HCMV strain by the Gaussia luciferase (GLuc) reporter assay.METHODS: The in vitro activity of each drug was first tested individually against HCMV by using the GLuc reporter assay. The activity of two-drug combinations consisting of ART and currently approved drugs, as well as letermovir or MBV, was then analysed by the Chou-Talalay method.RESULTS: The concentrations of GCV, FOS, CDV and ART that reduced the GLuc activity by 50% (ECvalues) were 3.92±1.64 µM, 62.45 ±8.39 µM, 0.68 ±0.19 µM and 3.86 ±1.25 µM, respectively, whereas those of MBV and letermovir were 64 ±22 nM and 2.50 ±0.83 nM, respectively. The combination of ART with GCV, CDV or MBV was associated with synergism, whereas combination of ART with FOS or letermovir resultedin moderate synergism. As expected, the combination of MBV with GCV was antagonistic.CONCLUSIONS: These results suggest that the combination of ART with the antiviral agents tested in this study could be an interesting strategy for the treatment of HCMV infections to reduce toxicity and drug-resistance development.

read more